Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19957128 | 0.88 | MET (0.52) | METAXLEGFRERBB2IMPDH2 | |
| SCHEMBL14217352 | 0.84 | EGFR (0.45) | MAP2K1METAXLAREGFR | |
| SCHEMBL29492471 | 0.82 | PDGFRB (0.55) | EGFRSRCPDGFRB | |
| SCHEMBL165285 | 0.82 | PDGFRB (0.55) | EGFRSRCPDGFRB | |
| SCHEMBL1895913 | 0.82 | SRC (0.50) | EGFRERBB2SRC | |
| Hydrochloric Acid SCHEMBL6432114 | 0.81 | SRC (0.49) | EGFRERBB2SRC | |
| SCHEMBL28439891 | 0.81 | EGFR (0.47) | METEGFRSRCPDGFRB | |
| Hydrochloric Acid SCHEMBL4463414 | 0.81 | PDGFRB (0.54) | EGFRSRCPDGFRB | |
| SCHEMBL13980692 | 0.79 | XDH (0.48) | EGFRSRC | |
| SCHEMBL4299967 | 0.78 | SRC (0.52) | MAP2K1EGFRERBB2SRCPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021225969-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | MAP2K1 1963/4885MET 4855/4885AXL 2498/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | MAP2K1 1963/4885MET 4855/4885AXL 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.